GW Pharmaceuticals is already well on its way to winning the first-ever U.S. approval for a cannabis-derived therapy. But an early trial suggests that these treatments could also be an effective way to fight one of most devastating forms of brain cancers: glioblastoma multiforme. Results so far show that the drug boosted brain cancer patients’ median survival rates by about six months compared to a placebo. Typically, this type of cancer ravages the brain and leaves 70% of patients dead within two years of being diagnosed.
http://fortune.com/2017/02/07/gw-pharmaceuticals-marijuana-brain-cancer/
